The global market for products seeking to tackle counterfeit pharmaceutical and cosmetics packaging will reach more than $80 billion by 2020, according to a report.
China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.
Australia could be going down the road of no longer allowing gene patents, New Zealand-based patent lawyer David Nowak said at the BIO International Convention yesterday.
The High Court of Australia has revealed it will hear oral arguments in the patent dispute between breast cancer survivor Yvonne D’Arcy and molecular diagnostic company Myriad Genetics on June 16 and 17.
The Australian health minister has revealed a series of reforms that will aim to reduce spending on patented drugs from the pharmaceutical industry.
Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi in certain Asian, Latin American and European countries.
The Foundation for AIDS Research has warned that the Trans-Pacific Partnership’s changes to IP policy could restrict access to affordable generic medicines in low and middle income countries.
Japanese drug maker Otsuka Holdings has agreed to buy Avanir Pharmaceuticals as part of a multi-billion dollar deal that could ease its potential patent woes.
Criminal gangs in Australia are branching away from traditional forms of counterfeiting and are targeting pharmaceuticals, an Australian customs official has revealed.
Indian drug maker Cipla has signed a deal with Salix Pharmaceuticals allowing the US-based company exclusive rights relating to the Rifaximin Complexes patent family.